[關(guān)鍵詞]
[摘要]
目的 探討加味左金丸聯(lián)合雷貝拉唑治療胃食管反流病的臨床療效。方法 選取2021年1月—2023年3月蘇州高新區(qū)人民醫(yī)院收治的胃食管反流病患者100例,隨機分為對照組(50例)和治療組(50例)。對照組患者口服雷貝拉唑腸溶膠囊,1次/d,20 mg/次。治療組患者在對照組基礎(chǔ)上口服加味左金丸,2次/d,6 g/次。兩組均連續(xù)治療8周。觀察兩組患者臨床療效,比較治療前后兩組患者臨床癥狀和SF-36量表評分及食管括約肌靜息壓。結(jié)果 治療后,治療組總有效率為90.00%,明顯高于對照組(74.00%,P<0.05)。治療后,兩組反流性疾病問卷(RDQ)總分、燒心、反食、反酸、胸部不適評分均明顯降低,而總體健康、生理功能、生理職能、社會功能、情感職能、軀體疼痛、生命活力、心理健康評分明顯升高(P<0.05),且治療組臨床癥狀和SF-36量表評分明顯好于對照組(P<0.05)。治療后,兩組患者食管下括約?。↙ES)靜息壓和食管上括約?。║ES)靜息壓明顯升高(P<0.05),且治療組明顯高于對照組(P<0.05)。結(jié)論 加味左金丸聯(lián)合雷貝拉唑治療胃食管反流病具有較好的療效,可改善患者的臨床癥狀和生活質(zhì)量,增加食管括約肌靜息壓。
[Key word]
[Abstract]
Objective To explore the curative effect of Jiawei Zuojin Pills combined with rabeprazole in treatment of gastroesophageal reflux disease. Methods Patients (100 cases) with gastroesophageal reflux disease in the People’s Hospital of SND from January 2021 to March 2023 were randomly divided into control (50 cases) and treatment (50 cases) group. Patients in the control group were po administered with Rabeprazole Sodium Enteric Capsules, 20 mg/time, once daily. Patients in the treatment group were po administered with Jiawei Zuojin Pills on the basis of the control group, 6 g/time, twice daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical evaluation was evaluated, the scores of clinical symptom and SF-36 scale, resting pressure of esophageal sphincter in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 90.00%, which was significantly higher than that of the control group (74.00%, P<0.05). After treatment, the total score of RDQ, the scores of heartburn, regurgitation, acid reflux and chest discomfort in two groups were significantly decreased, while the scores of overall health, physiological function, physiological function, social function, emotional function, physical pain, vitality and mental health were significantly increased (P<0.05), and the clinical symptoms and the score of SF-36 scale in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the resting pressure of LES and UES in two groups were significantly increased (P<0.05), and which in the treatment group were significantly higher than those in the control group (P<0.05). Conclusion Jiawei Zuojin Pills combined with rabeprazole has good effect in the treatment of gastroesophageal reflux disease, which can improve the clinical symptoms and quality of life of patients, increase the resting pressure of esophageal sphincter.
[中圖分類號]
R975
[基金項目]
江蘇省衛(wèi)生健康委科研項目立項項目(M2020037)